Alterity Therapeutics (ATHE) Competitors $4.89 +0.06 (+1.24%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$4.95 +0.06 (+1.23%) As of 10/17/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE vs. APLT, ELDN, THTX, FATE, NVCT, CRDF, MOLN, ANRO, ACOG, and CTORShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Applied Therapeutics (APLT), Eledon Pharmaceuticals (ELDN), Theratechnologies (THTX), Fate Therapeutics (FATE), Nuvectis Pharma (NVCT), Cardiff Oncology (CRDF), Molecular Partners (MOLN), Alto Neuroscience (ANRO), Alpha Cognition (ACOG), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. Its Competitors Applied Therapeutics Eledon Pharmaceuticals Theratechnologies Fate Therapeutics Nuvectis Pharma Cardiff Oncology Molecular Partners Alto Neuroscience Alpha Cognition Citius Oncology Alterity Therapeutics (NASDAQ:ATHE) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations. Do analysts prefer ATHE or APLT? Alterity Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 145.40%. Applied Therapeutics has a consensus price target of $4.13, indicating a potential upside of 222.27%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Applied Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Which has more risk & volatility, ATHE or APLT? Alterity Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Do insiders & institutionals believe in ATHE or APLT? 2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is ATHE or APLT more profitable? Alterity Therapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A Applied Therapeutics N/A -354.24%-144.16% Does the media refer more to ATHE or APLT? In the previous week, Applied Therapeutics had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for Applied Therapeutics and 1 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 1.00 beat Applied Therapeutics' score of 0.32 indicating that Alterity Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Alterity Therapeutics Positive Applied Therapeutics Neutral Which has better valuation and earnings, ATHE or APLT? Alterity Therapeutics has higher earnings, but lower revenue than Applied Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$7.87MN/AN/AApplied Therapeutics$460K400.72-$105.62M-$0.45-2.84 SummaryApplied Therapeutics beats Alterity Therapeutics on 7 of the 12 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.36M$3.43B$6.20B$10.53BDividend YieldN/A2.28%5.70%4.83%P/E RatioN/A23.1685.7027.13Price / SalesN/A468.51585.75179.61Price / CashN/A46.9237.1060.81Price / Book1.5810.4112.236.52Net Income-$7.87M-$52.77M$3.33B$276.93M7 Day Performance13.99%2.31%1.17%1.93%1 Month Performance9.15%12.59%6.85%2.19%1 Year Performance288.10%11.18%58.93%34.62% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics2.5655 of 5 stars$4.89+1.2%$12.00+145.4%+288.1%$43.36MN/A0.0010Positive NewsShort Interest ↓APLTApplied Therapeutics3.7617 of 5 stars$1.11-3.1%$4.13+273.3%-85.7%$160.57M$460K-2.4830News CoverageAnalyst ForecastELDNEledon Pharmaceuticals1.8097 of 5 stars$2.68-1.7%$10.00+273.8%+15.8%$159.58MN/A-2.2810News CoverageGap UpTHTXTheratechnologiesN/A$3.42+0.9%N/A+157.1%$157.21M$84.38M-17.99140High Trading VolumeFATEFate Therapeutics4.1539 of 5 stars$1.36-2.5%$3.30+143.5%-54.5%$156.04M$13.63M-0.93550NVCTNuvectis Pharma2.584 of 5 stars$6.13-1.1%$15.33+150.3%-18.8%$155.82MN/A-5.238News CoverageCRDFCardiff Oncology2.5455 of 5 stars$2.25-0.7%$10.63+373.3%-24.5%$149.29M$680K-2.5820Positive NewsMOLNMolecular Partners1.4795 of 5 stars$3.70-2.5%$8.00+116.5%-22.1%$149.20M$5.65M-1.78180Positive NewsAnalyst ForecastANROAlto Neuroscience2.1733 of 5 stars$5.49-6.6%$9.80+78.5%-57.8%$148.67MN/A-2.30N/AGap DownACOGAlpha Cognition2.322 of 5 stars$6.99-0.9%$20.00+186.1%N/A$146.09MN/A-4.37N/AAnalyst DowngradeShort Interest ↑CTORCitius Oncology2.0535 of 5 stars$1.74+0.6%$6.00+244.8%+37.1%$145.31MN/A0.00N/ANews Coverage Related Companies and Tools Related Companies APLT Competitors ELDN Competitors THTX Competitors FATE Competitors NVCT Competitors CRDF Competitors MOLN Competitors ANRO Competitors ACOG Competitors CTOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHE) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHE Stock Alerts